Start here: what obesity is
Obesity is a chronic energy-balance disorder where body fat becomes sustainedly excessive, with impacts across cardiometabolic, liver, joint, sleep, and cancer risk pathways [1] [2]. It is not simply “low willpower”; it is a systems problem spanning appetite signaling, adipose biology, metabolism, social context, medications, sleep, and behavior [3] [4] [5].
Publicly, two ideas are important: first, a measured phenotype matters more than a body-shape intuition; second, intervention quality depends on mechanism, not just weight scale targets [6] [2].
Pillar 1: measurements
Body-mass index (BMI) remains the standard screening measure for diagnosis and public communication, but it is only one layer [6].
Waist circumference and fat distribution track risk in many populations where BMI alone misses central adiposity burden [7] [8].
Metabolic panels and comorbidity markers add interpretive power: glucose control, lipids, blood pressure, liver enzymes, and kidney markers distinguish phenotypes and guide treatment intensity [2] [4].
Imaging, when needed, refines phenotype (visceral fat burden, ectopic fat, sarcopenic patterns), especially for high-risk or therapy-selection decisions [9] [10].
Pillar 2: medicines
The current medication landscape now has both glucose-directed and obesity-directed classes that materially overlap [11] [12].
GLP-1-based therapies remain central because they reduce appetite and improve weight outcomes beyond glycemic effects, with data showing meaningful losses and cardiometabolic spillover in relevant cohorts [11] [13] [14].
Dual agonists and next-generation multiagonists (e.g., tirzepatide and newer combination-class agents) show larger average losses in trial settings and are changing the efficacy floor for nonsurgical care [12] [15] [16].
Mechanistic and adjunctive medications (e.g., pathways tied to glucose, insulin sensitivity, and appetite neurobiology) remain active but are increasingly selected by patient phenotype and response speed rather than one-size class rules [3] [7] [17].
Procedural pathways such as bariatric surgery are still relevant for severe obesity and selected comorbidity profiles, especially when metabolic risk remains high despite evidence-based therapy [18] [19].
Pillar 3: progress
Progress is now partly about choosing “how much and how durable” rather than “whether medication can reduce weight at all”:
- Early prevention and cardiometabolic coupling: weight-first strategies increasingly integrate blood-pressure and diabetes endpoints, not weight alone, in treatment goals [2] [20].
- Durability and regain: long-horizon planning now includes maintenance signals, retreatment cadence, and transition strategies after maximal benefit [21] [22] [23].
- Broader phenotype endpoints: metabolic dysfunction-associated steatotic liver disease (MASLD), inflammation, and functional outcomes are being linked directly to response claims [24] [25] [8].
- Access and implementation: trial efficacy is being translated through implementation studies, adherence support, and reimbursement-aware care pathways [19] [17].
A simple model: energy-balance / body-weight ODE
A first-order energy model useful for simulations starts from the dynamic body-weight literature's energy-imbalance framing [26]:
\[ \frac{dW}{dt}=\frac{\Delta E_{in}(t)-\Delta E_{out}(t)}{\rho} \]
where $W$ is body mass, $\Delta E_{in}$ net daily energy input above baseline maintenance, $\Delta E_{out}$ effective expenditure (including activity and therapy-related increases), and $\rho\approx 7700\,\text{kcal/kg}$ is the legacy 3500 kcal/lb energy-to-mass conversion scalar, used here as a short-run teaching approximation rather than a durable clinical forecast rule [27].
A simple medication/satiety input term can be written:
\[ \Delta E_{in}(t)=E_{in,0}\left(1-u_{sat}(t)-u_{meal}(t)\right) \]
Note the sign convention: $u_{sat}(t)$ and $u_{meal}(t)$ are suppression fractions, so therapy works by increasing them, which lowers $\Delta E_{in}$; setting them to zero returns intake to its untreated baseline $E_{in,0}$. Activity-support interventions act on the other term, increasing $\Delta E_{out}$. Both levers therefore push $dW/dt$ negative, and the equation above only reproduces weight loss if the signs are read that way.
This toy model matches short-to-medium-term behavior if interpreted as a policy simulation, not a full clinical predictor [26] [27] [11] [12] [6].
Dig deeper in lmmol
Related reviews in this series:
- Diabetes and the HbA1c biomarker — the incretin therapies central here were glucose drugs first.
- Hypertension — the cardiometabolic condition most often managed alongside weight.
The receptor targets behind the drug classes above:
- GLP-1 receptor — the target of semaglutide and the incretin class.
- Melanocortin-4 receptor — the hypothalamic node whose loss-of-function variants cause monogenic obesity.
- Ghrelin receptor — the orexigenic side of the appetite-signalling balance.
And one representative compound:
- Orlistat — the lipase inhibitor, acting on absorption rather than appetite.
For entities without a linked static page here, use the graph index, all diseases, or all proteins rather than guessing an entity URL.
Implementation & visualization hooks
lmvideo / diagramkit: render a closed-loop weight-control diagram showing intake, satiety signal, expenditure, adipose storage, and policy switches for maintenance versus escalation.